CB-5083: Targeting p97 AAA-ATPase to Disrupt Protein Homeostasis in Cancer Research

Introduction

The endoplasmic reticulum (ER) is pivotal in regulating protein synthesis, lipid metabolism, and cellular quality control mechanisms. At the intersection of these processes lies p97, also known as valosin-containing protein (VCP), a member of the AAA-ATPase family, which orchestrates the extraction and degradation of misfolded or damaged proteins from the ER membrane via the ubiquitin-proteasome pathway. Aberrant p97 activity is implicated in the pathogenesis of numerous malignancies, making it a compelling therapeutic target. In this context, CB-5083 has emerged as a highly selective and orally bioavailable p97 inhibitor, offering robust tools for interrogating protein homeostasis disruption and cancer cell apoptosis induction.

Molecular Mechanism of CB-5083: Selective p97 AAA-ATPase Inhibition

CB-5083 is a small molecule (C₂₄H₂₃N₅O₂, MW 413.47) designed to selectively inhibit the second ATPase domain (D2) of p97 by competing with ATP at its binding site. This selectivity is crucial: the D2 domain is primarily responsible for the ATPase activity required for substrate processing, while the D1 domain largely mediates hexamer assembly. Biochemically, CB-5083 demonstrates a potent IC₅₀ value of 15.4 nM against wild-type p97, reflecting its high affinity and specificity.

By impeding ATP hydrolysis within p97, CB-5083 effectively stalls the extraction of poly-ubiquitinated proteins destined for proteasomal degradation. This blockade leads to the accumulation of misfolded proteins in the ER, triggering the unfolded protein response (UPR) and activating downstream apoptotic pathways, notably involving caspase signaling. The resultant protein homeostasis disruption is cytotoxic to cancer cells, which often exhibit elevated proteostatic stress relative to normal tissues.

CB-5083 in Protein Degradation Pathway and ER Stress: Insights from Recent Research

Protein quality control in the ER is tightly coordinated by the ER-associated degradation (ERAD) pathway, wherein p97 is a central effector. Disruption of this pathway, as achieved by CB-5083, has profound consequences for cellular homeostasis—particularly in rapidly dividing tumor cells reliant on efficient protein turnover.

Recent advances in ER biology, as illustrated by Carrasquillo Rodríguez et al. (Molecular Biology of the Cell, 2024), have highlighted the interplay between protein degradation and lipid homeostasis. Their work elucidates how the stability of CTDNEP1, a nuclear envelope phosphatase regulating ER membrane synthesis, is governed by its regulatory subunit NEP1R1 and the proteasomal degradation machinery. Notably, p97 collaborates with the proteasome to extract ER membrane proteins for degradation—a process directly targeted by CB-5083. Thus, CB-5083 serves as a unique experimental tool to dissect the coupling between ER protein turnover, lipid metabolism, and cellular stress responses.

Preclinical Efficacy of CB-5083: Xenograft Tumor Models and Mechanistic Readouts

In vitro, CB-5083 prompts a dose-dependent accumulation of surrogate ERAD substrates, such as TCRα-GFP, within the ER, as well as poly-ubiquitinated proteins in diverse cancer cell lines (HEK293T, A549, HCT116). This accumulation correlates with robust induction of the unfolded protein response, culminating in caspase-mediated apoptosis. These effects are mechanistically linked to the unique ability of CB-5083 to arrest the protein degradation pathway at the level of substrate extraction, distinct from proteasome inhibitors which act downstream.

In vivo, the oral bioavailability of CB-5083 enables its use in mouse xenograft models of colorectal adenocarcinoma, non-small-cell lung cancer, and multiple myeloma. Oral administration yields significant tumor growth inhibition (TGI) of up to 63%, underscoring its translational promise. Importantly, the compound's pharmacokinetic properties (e.g., solubility in DMSO >20.65 mg/mL and ethanol >4.4 mg/mL; insoluble in water) and recommended storage conditions (–20°C; avoid long-term solution storage) facilitate its integration into preclinical workflows.

CB-5083 in Multiple Myeloma and Solid Tumor Research

The heightened sensitivity of multiple myeloma and certain solid tumors to disruptions in protein homeostasis provides a compelling rationale for targeting p97. CB-5083 has advanced into phase 1 clinical trials for these indications, reflecting its capacity to selectively induce apoptosis in malignant cells while sparing normal tissues. Mechanistically, the compound's action extends beyond mere proteasome inhibition, as it impedes the upstream extraction of misfolded proteins by p97, amplifying ER stress and activating the unfolded protein response more robustly than proteasome inhibitors alone.

This mechanistic distinction makes CB-5083 an invaluable chemical probe for discerning the contributions of p97-mediated protein extraction versus proteasomal degradation in tumor cell survival and therapeutic resistance. Researchers investigating the crosstalk between protein degradation, lipid synthesis (as regulated by CTDNEP1-NEP1R1 complexes), and metabolic adaptation in cancer can leverage CB-5083 to perturb these networks in a controlled, reversible manner.

Practical Considerations for Experimental Use of CB-5083

For laboratory studies, it is critical to consider CB-5083's physicochemical properties. As a solid compound, it is best dissolved in DMSO or ethanol using gentle warming and ultrasonic treatment to achieve optimal solubility. Stock solutions should be stored at –20°C and protected from repeated freeze-thaw cycles. Since CB-5083 is intended for research use only, and not for diagnostic or medical applications, rigorous handling and usage protocols must be followed.

Researchers are encouraged to quantify the accumulation of poly-ubiquitinated proteins, induction of UPR markers (e.g., CHOP, BiP), and activation of caspase signaling pathways as primary readouts of p97 inhibition. These molecular endpoints are essential for validating the specificity and efficacy of CB-5083 in cancer models and for exploring its broader effects on cellular homeostasis, including impacts on ER lipid metabolism as described by Carrasquillo Rodríguez et al. (2024).

Expanding the Scope: CB-5083 in Systems Biology and Organelle Homeostasis

While the principal focus of CB-5083 research has been on protein homeostasis disruption and tumor growth inhibition, recent insights into ER biology highlight the compound's broader utility. The study by Carrasquillo Rodríguez et al. (2024) demonstrates the nuanced relationship between protein quality control, ER membrane synthesis, and lipid storage, mediated in part by the proteasome and its associated cofactors like p97. By enabling precise, reversible inhibition of p97, CB-5083 offers researchers a means to interrogate how disturbances in protein degradation reverberate through lipid metabolic pathways, organelle morphology, and cellular stress responses.

For example, disruption of p97 activity by CB-5083 could be leveraged to study the consequences of sustained ER stress on CTDNEP1 stability, membrane biogenesis, and lipid droplet formation—expanding research avenues beyond oncology into metabolic disease and cell biology.

Conclusion

CB-5083 stands as a powerful, selective, and orally bioavailable p97 AAA-ATPase inhibitor, enabling rigorous investigation of protein degradation pathways, unfolded protein response activation, and cancer cell apoptosis induction. Its unique mechanism of action, targeting the extraction of poly-ubiquitinated proteins prior to proteasomal degradation, sets it apart from classical proteasome inhibitors. By integrating CB-5083 into experimental designs, researchers can interrogate the interplay between protein quality control, ER stress, and tumorigenesis, as well as emerging questions at the interface of lipid metabolism and organelle dynamics.

While earlier articles such as "CB-5083: A Selective p97 Inhibitor for Disrupting Protein..." have addressed the core pharmacological properties and anti-tumor effects of CB-5083, the current piece extends the discussion by explicitly linking p97 inhibition to broader cellular quality control networks, including recent discoveries in ER membrane and lipid regulation (Carrasquillo Rodríguez et al., 2024). This article thus provides not only a mechanistic overview but also practical guidance and new perspectives for leveraging CB-5083 in advanced systems biology and disease research.